This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Joseph A. Lubitz, PhD; Leon Freeman, PhD; Ronald Okun, MD

JAMA. 1973;223(10):1109-1112.

Abstract
One hundred fifteen patients with inoperable adrenal cortical carcinoma were treated with mitotane (o,p' = DDD). Eighty-five percent of the patients with elevated urinary steroid levels showed a marked reduction, 61% of the patients whose conditions we were able to evaluate showed a measurable disease response, and 45% showed an overall clinical response. These results are all markedly better than those described in earlier reports. In previous reports earlier recognition of the disease and institution of chemotherapy with mitotane resulted in the improvements described. There was no evidence of serious organ poisoning, except for the effects upon the adrenal cortex. On the basis of these data, early diagnosis and treatment of inoperable adrenal cortical carcinoma with mitotane seem to be useful.

Author Affiliations
From the Department of Pharmacology, Cedars-Sinai Medical Center, Los Angeles (Drs. Freeman and Okun), and the departments of medical pharmacology and therapeutics and medicine, University of California, Irvine, College of Medicine (Dr. Okun), and the Pharmaceutical Department, Calbio Pharmaceuticals, La Jolla, Calif (Dr. Lubitz).

Footnotes
Reprint requests to Calbio Pharmaceuticals, Division of Calbiochem, PO Box 2948, San Diego, Calif 92112 (Dr. Lubitz).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Management of Endocrine Manifestations and the Use of Mitotane As a Chemotherapeutic Agent for Adrenocortical Carcinoma
Veytsman et al.
JCO 2009;27:4619-4629.
ABSTRACT | FULL TEXT  

Adjuvant Mitotane for Adrenocortical Cancer--A Recurring Controversy
Huang and Fojo
J. Clin. Endocrinol. Metab. 2008;93:3730-3732.
FULL TEXT  

Adrenocortical Carcinoma: Clinical Update
Allolio and Fassnacht
J. Clin. Endocrinol. Metab. 2006;91:2027-2037.
ABSTRACT | FULL TEXT  

Pigmentary retinopathy, macular oedema, and abnormal ERG with mitotane treatment
Ng et al.
Br J Ophthalmol 2003;87 :500-501.
FULL TEXT  

Low-Dose Monitored Mitotane Treatment Achieves the Therapeutic Range with Manageable Side Effects in Patients with Adrenocortical Cancer
Terzolo et al.
J. Clin. Endocrinol. Metab. 2000;85:2234-2238.
ABSTRACT | FULL TEXT  

Treatment of Adrenal Carcinomas
Schteingart et al.
Arch Surg 1982;117:1142-1146.
ABSTRACT  

Metastatic Adrenal Cortical Carcinoma: Prolonged Regression With Mitotane Therapy
Jarabak and Rice
JAMA 1981;246:1706-1707.
ABSTRACT  

Metastatic Adrenal Cortical Carcinoma: Documented Cure With Combined Chemotherapy
Ostuni and Roginsky
Arch Intern Med 1975;135:1257-1258.
ABSTRACT  

o,p'DDD Therapy in Invasive Adrenocortical Carcinoma
BECKER and SCHUMACHER
ANN INTERN MED 1975;82:677-679.
ABSTRACT